Related Experiment Video

Updated: May 20, 2025

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

"Biomarker analyses from randomized trials in clear cell renal cell carcinoma"

S Coca Membribes¹, T Powles¹

¹St Bartholomew's Hospital, W Smithfield, City of London, London EC1A 7BE.

Annals of Oncology : Official Journal of the European Society for Medical Oncology

|March 26, 2025

Abstract

No abstract available in PubMed .

More Related Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

A Next-generation Tissue Microarray ngTMA Protocol for Biomarker Studies

A Next-generation Tissue Microarray ngTMA Protocol for Biomarker Studies

Published on: September 23, 2014

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation.

ESMO open·2026

A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treatment regimen (MORPHEUS-Urothelial Carcinoma).

ESMO open·2026

Higher rates of immune-related adverse events in circulating tumor DNA (ctDNA)-negative patients following adjuvant checkpoint inhibitor therapy.

ESMO open·2026

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Nivolumab plus gemcitabine-cisplatin for unresectable or metastatic urothelial carcinoma: health-related quality-of-life analyses from the phase III CheckMate 901 trial.

ESMO open·2026

Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

See all related articles